Helicobacter pylori and gastric mucosal interface

The gastric mucus layer and Helicobacter pylori surface/enzymes represent a complex therapeutic interface involved in the pathogenesis of chronic gastritis and peptic ulcers (StatPearls, 2023). Helicobacter pylori is a Gram-negative bacterium that colonizes the gastric mucosa, utilizing the enzyme urease to neutralize stomach acid by producing ammonia, thereby creating a habitable microenvironment (PubMed, PMID: 11218379). The bacterium penetrates the gastric mucus layer using flagellar motility and adheres to epithelial cells via surface adhesins like Blood group antigen-binding adhesin (BabA) (PubMed, PMID: 12443350). Once attached, it delivers virulence factors such as Cytotoxin-associated gene A (CagA) and Vacuolating cytotoxin A (VacA), which disrupt host cell signaling and induce chronic inflammation (UniProt, P12914). Therapeutic strategies typically involve a combination of antibiotics to eliminate the bacteria and proton pump inhibitors to raise gastric pH, which enhances antibiotic stability and promotes mucosal healing (NIH, 2022). This target complex is critical for understanding the transition from simple infection to gastric malignancies like adenocarcinoma and MALT lymphoma (WHO, 2020).

Other names

Gastric mucus layerHelicobacter pylori surface enzymesHelicobacter pylori urease complexGastric mucosal barrier

Bacterial cell wall synthesis inhibition, protein synthesis inhibition, DNA synthesis disruption, and urease inhibition (StatPearls, 2023).